Minna Tanner

Tampere, Finland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 28 publications

Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer.

Real-world implementation and cost impact analysis of Oncotype DX testing in early-stage breast cancer.

Journal: PloS one

Published: November 09, 2025

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.

Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for ERBB2-Positive Breast Cancer: A Secondary Analysis of the SOLD Randomized Clinical Trial.

Journal: JAMA network open

Published: August 26, 2024

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer.

Journal: NEJM evidence

Published: February 06, 2024

Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.

Neuropilin-1 and placental growth factor as prognostic factors in metastatic breast cancer.

Journal: BMC cancer

Published: December 14, 2023

A national precision cancer medicine implementation initiative for Finland.

A national precision cancer medicine implementation initiative for Finland.

Journal: Acta oncologica (Stockholm, Sweden)

Published: December 04, 2023

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.

Adjuvant Capecitabine for Early Breast Cancer: 15-Year Overall Survival Results From a Randomized Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 12, 2022

Decellularized In Vitro Capillaries for Studies of Metastatic Tendency and Selection of Treatment.

Decellularized In Vitro Capillaries for Studies of Metastatic Tendency and Selection of Treatment.

Journal: Biomedicines

Published: December 17, 2021

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.

First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.

Journal: Cancer immunology, immunotherapy : CII

Published: November 02, 2020

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.

Triple-negative and HER2-positive breast cancers found by mammography screening show excellent prognosis.

Journal: Breast cancer research and treatment

Published: October 13, 2020

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).

Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).

Journal: Clinical and translational science

Published: April 09, 2020

In Vitro Vascular Network Modified to Function as Culture Platform and Angiogenic Induction Potential Test for Cancer Cells.

In Vitro Vascular Network Modified to Function as Culture Platform and Angiogenic Induction Potential Test for Cancer Cells.

Journal: International journal of molecular sciences

Published: February 03, 2020

Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.

Low Plasma IL-8 Levels During Chemotherapy Are Predictive of Excellent Long-Term Survival in Metastatic Breast Cancer.

Journal: Clinical breast cancer

Published: December 06, 2018

Showing 1-12 of 28

Last Updated: 09/26/2026